Business Wire

City of Hope and Hospital Israelita Albert Einstein Sign Agreement to Advance Cancer Care in Latin America

1.4.2021 17:00:00 EEST | Business Wire | Press release

Share

City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, today announced that it will extend its leading-edge cancer expertise to South America via an education agreement with Hospital Israelita Albert Einstein, a top cancer center in Latin America.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210401005185/en/

The three-year agreement calls for City of Hope to share its specialized cancer expertise with Hospital Israelita Albert Einstein’s oncology residents and clinical staff. City of Hope will provide educational experiences and host multidisciplinary tumor boards. Both institutions will explore potential innovative collaborations in precision oncology and research.

“This agreement marks another milestone moment, allowing City of Hope to extend its mission to eliminate cancer to a new continent,” said Harlan Levine, M.D., president of strategy and business ventures at City of Hope, which is headquartered near Los Angeles.

“Hospital Israelita Albert Einstein has an exceptional medical team,” Levine added. “City of Hope will offer our best-in-class expertise as a comprehensive cancer center to both their residents in training and clinical staff. We hope to collaborate with our Latin American colleagues to improve cancer care outcomes not only in São Paulo, but also throughout Brazil and Latin America.”

Among other services, City of Hope will provide a virtual multidisciplinary tumor board that will initially focus on gastrointestinal, genitourinary, lung and brain cancers. Hospital Israelita Albert Einstein physicians will share specific patient cases with complex issues involving molecular diagnostics, immunotherapy and innovations in cancer care delivery for review and discussion. City of Hope will also provide educational webinars and offer professional training on topics such as genetic testing, supportive care services and nursing.

Sidney Klajner, M.D., Ph.D., president of Hospital Israelita Albert Einstein, said, “We will incorporate City of Hope’s multidisciplinary approach to oncology precision medicine to address the cancer burden in Brazil. Together with City of Hope, we hope to collaborate on molecular diagnostics and innovative care advancements for the benefit of patients in Latin American and beyond.”

Hospital Israelita Albert Einstein has been ranked as the best hospital in Latin America by the America Economia Business Intelligence Unit for 12 years in a row. Additionally, it is positioned 36th overall globally and 21st for specialized oncology on Newsweek’s ranking of the World’s Best Hospitals 2021.

This collaborative agreement was made possible through efforts by City of Hope’s Center for International Medicine (CIM), which seeks to collaborate with international organizations to improve cancer and diabetes care for more people worldwide. CIM works with governments, hospitals, private companies and investors, and offers a range of services in the areas of clinical research and innovation, education and professional development.

About City of Hope

City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hope’s translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin, monoclonal antibodies, and numerous breakthrough cancer drugs are based on technology developed at the institution. Translational Genomics Research Institute (TGen) became a part of City of Hope in 2016. AccessHope TM, a wholly owned subsidiary, was launched in 2019, dedicated to serving employers and their health care partners by providing access to City of Hope’s exceptional cancer expertise. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nation’s “Best Hospitals” in cancer by U.S. News & World Report. Its main campus is located near Los Angeles, with additional locations throughout Southern California and in Arizona. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.

About Hospital Israelita Albert Einstein

Hospital Israelita Albert Einstein is a not-for-profit health care system based in São Paulo, Brazil. It encompasses activities in health care delivery, teaching, research, innovation and consultancy. In the private setting, the system manages a 600-bed general hospital and 10 satellite units spread around the greater metropolitan area of São Paulo and is dedicated to diagnostics and ambulatory medicine. In the public setting, the system manages two hospitals, with 600 beds in total and 24 ambulatory units. In 1999, the hospital became the first hospital outside of the U.S. to be accredited by Joint Commission International. It is currently the strategic partner of the Institute for Healthcare Improvement in Latin America.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Zen Vuong
626-409-9367
zvuong@coh.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentations at AAD include: Late-Breaking Oral Presentations Hidradenitis Suppurativa Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa: 54-Week Efficacy and Safety Results From the STOP-HS1 & STOP-HS2 Phase 3 Studies (Session: S034 – Late-Breaking Research: Sess

MUSASHI JAPAN by TAIMATSU Launches “Road to Shogun” – A Journey Through Craftsmanship and Discovery20.3.2026 14:58:00 EET | Press release

Musashi Japan by TAIMATSU Co., Ltd., a contemporary Japanese knife brand rooted in the spirit of craftsmanship and cultural harmony, has announced its newest experiential campaign: “Road to Shogun.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320887471/en/ Designed as the brand’s most ambitious customer journey to date, the campaign invites visitors to explore participating Musashi Japan stores while discovering the traditions, culture and craftsmanship that inspire the brand. Inspired by the journey towards mastery, the experience encourages participants to progress through a series of ranks whilst visiting stores and unlocking rewards that celebrate elements of everyday Japanese culture. At Musashi Japan, craftsmanship is not only about the final product, but also about the path taken to achieve mastery. The Road to Shogun reflects this philosophy by guiding customers through a journey that mirrors the dedication, cu

Futur Delivers Strong Growth and Record Profit in 202520.3.2026 13:05:00 EET | Press release

"2025 was a record year for Futur. In a market characterized by sharp market fluctuations, Futur continued to invest, grow and deliver strong results. Behind this record performance is stable customer growth, strong inflows and cost discipline. Our close cooperation with over 60 partners gives customers the freedom to choose the asset management and advisory services that best suit them. The strategy of letting the customer choose is appreciated, which is reflected in us welcoming more than 21,000 new customers during the year", says Torgny Johansson, CEO of Futur. "We are optimistic about the future. Futur has great opportunities to continue growing in the coming years by developing innovative and efficient services for savings and pensions. I am proud of how all employees have purposefully embraced our strategy and continue to work towards the goal of reaching 500 billion kronor in savings capital with the current organization", concludes Torgny Johansson, CEO of Futur. Key highlight

Lyten to Establish a Lyten Industrial Hub in Poland20.3.2026 13:00:00 EET | Press release

Lyten, the supermaterial applications company and global leader in an energy storage, has announced its interest in establishing a Lyten Industrial Hub in Poland. In 2026, Lyten will conduct a feasibility study to assess manufacturing requirements for Lyten products, potential private and public partnerships, and the necessary energy and utility infrastructure. The industrial hub will be built around Lyten Dwa – the energy storage production plant and R&D center in Gdańsk. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320045026/en/ Lyten Voltpack Mobile System in front of Lyten Dwa plant in Gdansk, Poland In February 2026, Lyten announced the establishment of its first Industrial Hub in Skellefteå, Sweden, on the site of the former Northvolt Ett plant, which it recently acquired. It will combine battery production with a data center with a capacity of up to 1 GW, being built by EdgeConneX. Once it reaches full production

PUMA Reveals Its Most Powerful International Football Kit Lineup yet on the Streets of New York City20.3.2026 09:00:00 EET | Press release

Global sports company PUMA unveiled its new national team kits for 11 nations with a street-level event at Domino Square in New York City, that placed football, music, food, and culture at the center stage in a celebration of the game. Rather than launching in a stadium setting or in a cinematic brand film, PUMA chose to reveal the kits in play, worn first by local community players from each nation on the streets of New York. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320641449/en/ Reinforcing its status as a leading force in football kits at this summer’s competition, PUMA unveiled jerseys for 11 nations, including the most prominent African partner federations of any brand in the tournament, in a community-first celebration of football, music, and culture in New York City. Four continents are united under 11 nations: Portugal, Morocco, Ghana, Paraguay, Senegal, Côte d’Ivoire, Czech Republic, Switzerland, New Zealan

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye